Enhanced T-Cell Responses to Glioma Cells Coated With the Anti-EGF Receptor Antibody and Targeted to Activating FcγRs on Human Dendritic Cells
The DOI matches its Crossref record; 29 of the 31 references it cites were found in a registry or an index.
Abstract
The induction of effective immune responses to tumor vaccines requires the preferential activation of effector T cells relative to regulatory or suppressive T cells. Glial tumors commonly overexpress the epidermal growth factor receptor (EGFR), which can be targeted by monoclonal antibodies. Here we show that the coating of glial tumor cells with a clinical grade anti-EGFR antibody, cetuximab, leads to enhanced tumor-specific, interferon-gamma producing CD8+ T cells by dendritic cells (DCs). The selective targeting of monoclonal antibody coated glioma cells to activating Fcgamma receptors (FcgammaRs) on DCs, which is achieved with a blocking antibody to the inhibitory form of FcgammaR, leads to the induction of antitumor immunity without the need for an exogenous maturation stimulus. Importantly, this approach reduces the concurrent induction of regulatory T cells, which can also be depleted to further enhance immunity. These data suggest that immunity to EGFR expressing tumors, including glioma, can be enhanced through the concerted function of antitumor monoclonal antibodies, activating FcgammaR, and DCs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, various EGFRtargeting agents improve MHC class I antigen presentation by cancer cells (Lizotte et al., 2018; Pollack et al., 2011) and favor the uptake of tumor material by DCs (Banerjee et al., 2008; Nigro et al., 2019) as well as their ability to prime T cells and promote NK-cell activation in the absence of additional immunostimulatory signals (Banerjee et al., 2008; Lee et al., 2”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Banerjee et al., 2008
In the citing paper
“enhanced uptake of tumor material and cross-presentation by DCs, followed by priming of T cells and activation of NK cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Banerjee et al., 2008
Citations
Cites
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694 · cited 1×
“Cetuximab (erbitux) is a chimeric mAb against the human EGFR, which has shown clinical activity in colon and other epithelial cancers, and is approved for the therapy of colon cancer.(8) Cetuximab has also shown promising activity against glioma in preclinical models(9,10) and is now in early phase trials in glioma pa…”
BackgroundDeAngelis, L. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101113440207 · Cited by 1,663
Ravetch, J. V., & Bolland, S. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,657 · cited 1×
“The net result of the stimulation of these receptors depends upon the degree to which each type of receptor is expressed by a given cell and also finds its corresponding form of antibody ligand.(16) Recently, we have shown that selective blockade of the inhibitory FcgR on human monocyte-derived DCs (MoDCs) leads to DC…”
BackgroundMonoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Théry, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.371 · Cited by 898
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 740
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630 · cited 2×
“Overexpression of EGFR in glioblastoma is also associated with an aggressive tumor phenotype and shorter survival.(4) On the basis of these considerations, EGFR and its mutant isoform, EGFRvIII, are under investigation as molecular targets for glioma therapy.”
BackgroundFecci, P. E., Mitchell, D. A., Whitesides, J. F., Xie, W., Friedman, A. H., Archer, G. E., Herndon, J. E., Bigner, D. D., Dranoff, G., & Sampson, J. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3773 · Cited by 617 · cited 1×
“Recent studies have indeed observed that glioma patients may have increased proportions of Tregs and that these may limit the efficacy of DC vaccination.(31,32) Our data show 2 important points in this regard: (1) depletion or inactivation of Tregs may boost the generation of effector T cells by tumor-loaded DCs; and…”
ResultLiau, L. M., Prins, R. M., Kiertscher, S. M., Odesa, S. K., Kremen, T. J., Giovannone, A. J., Lin, J.-W., Chute, D. J., Mischel, P. S., Cloughesy, T. F., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0464 · Cited by 543
Yu, J. S., Liu, G., Ying, H., Yong, W. H., Black, K. L., & Wheeler, C. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3505 · Cited by 537
Cited by
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6360 · Cited by 320
Monoclonal antibodies for cancer immunotherapy
Weiner, L. M., Dhodapkar, M. V., & Ferrone, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60251-8 · Cited by 307
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Metadata
- Authors
- Banerjee, D., Matthews, P., Matayeva, E., Kaufman, J. L., Steinman, R. M., & Dhodapkar, K. M.
- Affiliations
- Rockefeller University (US)
- ORCID
- Dhodapkar, Kavita M.
- Venue
- Journal of Immunotherapy
- Published
- 2008-02
- Volume
- 31
- Issue
- 2
- Pages
- 113-120
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W2039061028
- Cited by
- 31
- References
- 31
- Citations by year
- 2022: 2 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 1 · 2012: 2
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Immunotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (2m01rr000102-41)
- National Institute of Allergy and Infectious Diseases (K08AI054375, P01-AI51573, AI054375, P01AI051573)
- National Center for Research Resources (M0-1 RR00102)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- glioma, epidermal growth factor receptor, cetuximab, anti-EGFR monoclonal antibody, dendritic cells, CD8+ T cells, interferon-gamma, regulatory T cells, tumor-specific immunity, cancer vaccines, monoclonal antibody therapy, antitumor immunity
- MeSH terms
- Cetuximab, Antibodies, Monoclonal, Antineoplastic Agents, Cell Differentiation, Dendritic Cells, Glioma, Humans, Interferon-gamma, Lymphocyte Activation, Cytokines, Receptors, IgG, Antigen Presentation, CD8-Positive T-Lymphocytes, Coculture Techniques, Chemokines, Cell Line, Tumor, T-Lymphocytes, Regulatory, Forkhead Transcription Factors, Interleukin-2 Receptor alpha Subunit, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced T-Cell Responses to Glioma Cells Coated With the Anti-EGF Receptor Antibody and Targeted to Activating FcγRs on Human Dendritic Cells. https://app.cochat.ai/papers/10.1097/cji.0b013e31815a5892
- The paper
- Banerjee, D., Matthews, P., Matayeva, E., Kaufman, J. L., Steinman, R. M., & Dhodapkar, K. M. (2008). Enhanced T-Cell Responses to Glioma Cells Coated With the Anti-EGF Receptor Antibody and Targeted to Activating FcγRs on Human Dendritic Cells. Journal of Immunotherapy. https://doi.org/10.1097/cji.0b013e31815a5892
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.